雷帕格林胺通过向FOXO3/lumican/p53轴来抑制HC的发展和进展
Yifei Tan1,2, Yongjie Zhou1, Wei Zhang3
1Department of Liver Transplantation Center and Laboratory of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, China.
雷帕格林胺 (RPG) 向FOXO3/lumican/p53通路,抑制肝细胞癌 (HCC) 的进展. 这项研究揭示了lumican.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 异常的N链 glycoproteins 与各种癌症有关.
- 了解它们在肝细胞癌 (HCC) 中的作用对于治疗策略至关重要.
研究的目的:
- 探索HCC中异常表达的葡萄糖蛋白.
- 调查它们在HCC进展中的作用,并确定潜在的治疗点.
主要方法:
- 质谱和免疫组织化学 (IHC) 确定了糖蛋白.
- 在体外和体内试验评估了lumican在HCC中的作用.
- 染色体免疫沉 (ChIP) 和光酶测定确定了转录因子.
- 评估了Repaglinide (RPG) 对FOXO3/lumican/p53轴的影响.
主要成果:
- 在HCC中,Lumican的调节升高,与预后不佳相关.
- 通过影响p53/p21通路,Lumican knockdown抑制了HCC的生长.
- FOXO3被确定为lumican的转录因子.
- 通过破坏FOXO3/lumican/p53轴,RPG抑制了HCC的进展.
结论:
- 雷帕格林化物 (RPG) 防止HCC的发展和进展.
- FOXO3/lumican/p53轴是RPG在HCC中准的一个关键路径.
更多相关视频
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Abnormal Proliferation
Hedgehog Signaling Pathway
Cell Specific Gene Expression
